# Nevanac 3-Month Safety Study With QID Dosing

> **NCT00332774** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 149 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Nepafenac ophthalmic solution 0.1%
- **DRUG:** Ketorolac Tromethamine ophthalmic solution 0.4%
- **OTHER:** Nepafenac ophthalmic suspension vehicle

## Key facts

- **NCT ID:** NCT00332774
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2012-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332774, "Nevanac 3-Month Safety Study With QID Dosing". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00332774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*